Home Monitoring in the Management of Hypertension and Diabetes Mellitus
A Trial of the Use of Multiple Automated Measuring Devices in the Management of Patients With Hypertension and Type 2 Diabetes Mellitus
調査の概要
詳細な説明
Background:
Approximately 40% of type 2 diabetes patients are also with hypertension. There are many risk factors in these patients, and so it's difficult to manage these patients. With the improvement of the accuracy of automated measuring devices, the patients can use these devices to monitor blood pressure, blood glucose, body weight, visceral fat and other indicators at home, and contribute their own participation in the management of there own diseases. The home monitoring may improve the management of this chronic disease, and may decrease the incidence of fatal disease such as stroke, myocardial infarction, heart failure, renal dysfunction and other serious diseases.
Large-scale research will carry out to prove that whether home monitoring is valuable for preventing the incidence of fatal disease such as stroke, myocardial infarction, heart failure, renal dysfunction. And in the first, it is necessary to conduct a small sample (n = 100), short observation time (six months) research, to monitor blood pressure, blood glucose, body weight and other indicators of intermediate target detection, to explore the feasibility to carry out such large-scale research.
Objective:
In hypertensive and type 2 diabetes patients, conducted an open randomized controlled trial to explore the patient's own use blood pressure monitors, blood glucose meter and pedometer at home, and use the body composition measurement instruments in clinic, is to be more effective control of blood pressure, blood glucose, body weight, and reduce the risk of patients with albuminuria.
Inclusion criteria:
- Regardless of whether they are currently receiving antihypertensive therapy, systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than90 mmHg.
- Whether or not use oral hypoglycemic agents or insulin injections, the fasting plasma is higher than 7.0 mmol/L, or postprandial blood glucose higher than 11.1 mmol/L.
Exclusion criteria:
- with life-threatening disease.
- With the various effects of metabolic diseases such as hyperthyroidism, hypothyroidism, etc.
- stroke, myocardial infarction and other serious cardiovascular and cerebrovascular diseases occurred within 3 months.
- serum creatinine level hugher than 176.8 mol/L.
- Dementia or severe cognitive decline.
- unable to do a long-term follow-up study or do not agree to participate in this trial.
Sample estimates and statistical analysis:
In accordance with 6-month follow-up, the average difference between the two groups, systolic blood pressure 3 mmHg, glycated hemoglobin 0.2%, under the conditions of a= 0.05 and b= 0.10, the research needs of each group of about 50 patients, a total of 100.
Major findings of the statistics using t test comparing the two groups after 6 months follow-up observations from the baseline change in the margin, and calculated 95% confidence interval. At the same time will also use non-parametric Wilcoxon test were compared blood pressure, blood glucose and so many follow-up results of repeated measurements.
研究の種類
入学 (予想される)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Regardless of whether they are currently receiving antihypertensive therapy, systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg.
- Whether or not use oral hypoglycemic agents or insulin injections, the fasting plasma is higher than 7.0 mmol/L, or postprandial blood glucose higher than 11.1 mmol/L.
Exclusion Criteria:
- With life-threatening disease.
- With the various effects of metabolic diseases such as hyperthyroidism, hypothyroidism, etc.
- Stroke, myocardial infarction and other serious cardiovascular and cerebrovascular diseases occurred within 3 months.
- Serum creatinine level higher than 176.8 mmol/L
- Dementia or severe cognitive decline
- Unable to do a long-term follow-up or do not agree to participate in this trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:no home monitoring
no automated measuring devices for patients use at home
|
automated measuring devices for patients using at home
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
blood pressure, blood glucose, body weight and visceral fat levels.
時間枠:3,6 months
|
3,6 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
albuminuria
時間枠:3 months, 6 months
|
3 months, 6 months
|
協力者と研究者
捜査官
- 主任研究者:Jiguang Wang, Doctor、Shanghai Jiao Tong University School of Medicine
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
高血圧症の臨床試験
-
University of Sao Paulo General Hospitalまだ募集していませんCOPD | 肺疾患および/または低酸素症に続発する肺高血圧症 | Pulmnary Hypertension
Home monitoringの臨床試験
-
Karolinska Institutet完了
-
Philips Clinical & Medical Affairs Global募集
-
University of North Carolina, Chapel HillNational Institute of Nursing Research (NINR)募集
-
University Health Network, TorontoSunnybrook Health Sciences Centre; University of Toronto完了